Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : to reduce size of management board to five

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/10/2019 | 10:56am EDT
FILE PHOTO:    Logo of Bayer AG is pictured ahead of the the annual results news conference of the German drugmaker in Leverkusen

FRANKFURT (Reuters) - Bayer management board members Hartmut Klusik and Kemal Malik will leave at the end of the year without a replacement, as the German drugmaker reduces its board to five seats to cut costs.

"By streamlining the structure of the Board of Management, we are optimizing the allocation of responsibilities and contributing to the company's ongoing efficiency program," Werner Wenning, chairman of the non-executive supervisory board, said in a statement on Tuesday.

Malik is responsible for innovation as well as the Asia Pacific region while Klusik holds the position of labor director and is responsible for technology and sustainability.

The company will continue to push for innovation and to develop its network of partnerships, Chairman Wenning added.

Bayer said last year it would lean more strongly on external firms and institutions for a better drug development pipeline, which most analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.

In late 2018 Bayer also unveiled plans to slash 12,000 jobs, about one in 10 of its global work force, and set out on an asset divestment campaign that included its animal health division.

Bayer is seeking to reduce debt after the $63 billion takeover of seed maker Monsanto last year. Its share price has been depressed by U.S. litigation over an alleged cancer-causing effect of Monsanto weedkillers.

The company has reaffirmed the product is safe to use, citing backing by health regulators but analysts on average expect a litigation settlement of more than $10 billion.

Responsibility for innovation would be split among divisional heads of Bayer's pharmaceuticals, crop science and consumer health businesses.

About a year ago, Klusik, Bayer's labor director and board member responsible for technology, was given a contract extension for one year until the end of 2019.

Sources familiar with the company said at the time the extension of Klusik's contract had been in doubt because drug production at Bayer's Leverkusen plant in Germany was found to be substandard by U.S. regulators in February and this fell under his remit.

But Bayer hung on to him to have an experienced head of personnel oversee an overhaul of the research and development operations.

Bayer Chief Executive Werner Baumann will take over as head of personnel next year, adding the title of labor director.

(Reporting by Ludwig Burger; Editing by Michelle Martin)

By Ludwig Burger

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
09/11BAYER : opens application window for Grants4Traits™ and Grants4Biologicals..
PU
09/10BAYER : to reduce size of management board to five
RE
09/10BAYER : to Reduce Size of Management Board
DJ
09/10BAYER : reduces size of Board of Management from seven to five members
PU
09/10BAYER : launches latest fungicide innovation, iblon™ technology
PU
09/10Elliott Appears to Revert to Old Form -- WSJ
DJ
09/09Big Ag wants a cut of booming fake-meat market
RE
09/09Germany Offers a Model to Corporate America on Labor Relations
DJ
09/06BAYER : Yields more than doubled during 4-year project with smallholder farmers
PU
09/06BAYER : Counters Accusations Involving Monsanto Weedkiller
DJ
More news
Financials (EUR)
Sales 2019 46 036 M
EBIT 2019 7 933 M
Net income 2019 3 131 M
Debt 2019 37 298 M
Yield 2019 4,20%
P/E ratio 2019 21,6x
P/E ratio 2020 14,0x
EV / Sales2019 2,19x
EV / Sales2020 2,06x
Capitalization 63 292 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 78,94  €
Last Close Price 67,72  €
Spread / Highest target 81,6%
Spread / Average Target 16,6%
Spread / Lowest Target -42,8%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG12.07%69 606
JOHNSON & JOHNSON1.34%341 878
ROCHE HOLDING LTD.12.28%234 825
MERCK AND COMPANY7.36%210 028
PFIZER-15.62%203 709
NOVARTIS16.65%198 073